About Beam Therapeutics Inc.
https://www.beamtx.comBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
CEO
John M. Evans
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 153
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
B of A Securities
Buy
Jones Trading
Buy
Scotiabank
Sector Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:11.69M
Value:$414.04M
ARK INVESTMENT MANAGEMENT LLC
Shares:11.04M
Value:$390.89M
FARALLON CAPITAL MANAGEMENT LLC
Shares:10.06M
Value:$356.33M
Summary
Showing Top 3 of 246
About Beam Therapeutics Inc.
https://www.beamtx.comBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $9.7M ▲ | $26.74M ▼ | $-112.73M ▼ | -1.16K% ▲ | $-1.1 ▼ | $-107.17M ▲ |
| Q2-2025 | $8.47M ▲ | $26.86M ▼ | $-102.29M ▲ | -1.21K% ▲ | $-1 ▲ | $-114.61M ▼ |
| Q1-2025 | $7.47M ▼ | $27.94M ▼ | $-109.27M ▼ | -1.46K% ▼ | $-1.24 ▼ | $-113.76M ▼ |
| Q4-2024 | $30.07M ▲ | $28.66M ▲ | $-90.35M ▲ | -300.51% ▲ | $-1.09 ▲ | $-94.59M ▲ |
| Q3-2024 | $14.27M | $26.52M | $-96.67M | -677.47% | $-1.17 | $-101.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.07B ▼ | $1.31B ▼ | $345.08M ▲ | $966M ▼ |
| Q2-2025 | $1.15B ▼ | $1.39B ▼ | $344.34M ▲ | $1.05B ▼ |
| Q1-2025 | $1.22B ▲ | $1.47B ▲ | $343.78M ▼ | $1.12B ▲ |
| Q4-2024 | $850.74M ▼ | $1.1B ▼ | $370.28M ▼ | $733.54M ▼ |
| Q3-2024 | $925.76M | $1.17B | $380.05M | $791.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-112.73M ▼ | $-81.48M ▼ | $65.66M ▲ | $1.68M ▲ | $-14.17M ▲ | $-86.49M ▼ |
| Q2-2025 | $-102.29M ▲ | $-76.45M ▲ | $-170.41M ▼ | $1.11M ▼ | $-245.75M ▼ | $-79.59M ▲ |
| Q1-2025 | $-109.27M ▼ | $-103.88M ▼ | $-125.09M ▼ | $473.38M ▲ | $244.41M ▲ | $-106.95M ▼ |
| Q4-2024 | $-90.35M ▲ | $-76.36M ▲ | $126.28M ▲ | $3.44M ▲ | $53.36M ▲ | $-79.33M ▲ |
| Q3-2024 | $-96.67M | $-88.13M | $24.7M | $1.26M | $-62.16M | $-89.7M |
CEO
John M. Evans
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 153
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
B of A Securities
Buy
Jones Trading
Buy
Scotiabank
Sector Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:11.69M
Value:$414.04M
ARK INVESTMENT MANAGEMENT LLC
Shares:11.04M
Value:$390.89M
FARALLON CAPITAL MANAGEMENT LLC
Shares:10.06M
Value:$356.33M
Summary
Showing Top 3 of 246